S&P Futures
4,227.25+5.00(+0.12%)Dow Futures
33,817.00+12.00(+0.04%)Nasdaq Futures
14,203.75+38.25(+0.27%)
10x Genomics, Inc. (TXG)
- GlobeNewswire
10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping
Fueling Discovery in Preserved Tissue Samples to Advance Clinical Translational ResearchPLEASANTON, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced it is shipping its new Visium Spatial Gene Expression for FFPE (formalin-fixed and paraffin-embedded) assay. The offering gives researchers access to the whole transcriptome across their entire tissue, enabling true unbiased discovery in FFPE samples for the first time. The product addresses customer demand
- Motley Fool
Here's Why 10x Genomics Can't Satisfy Short-Term Investors
10x Genomics (NASDAQ: TXG), which is focused on helping researchers study genomic changes on a cellular level, beat Wall Street expectations in the first quarter, but shares of the company fell substantially. In this video from Motley Fool Live, recorded on May 10, Fool.com contributors Brian Orelli and Keith Speights discuss why the share price dropped and why the short-term move shouldn't affect long-term investors. Brian Orelli: Not every company had an impressive first quarter.
- Investor's Business Daily
10x Genomics Stock Shows Rising Price Performance With Jump To 83 RS Rating
10x Genomics Inc Cl A shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.
